Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars
  • Regulatory

Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars

Big Molecule Watch

On May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S.

Read full story

pharminent June 4, 2026 (Last updated: June 5, 2026)

Big Molecule Watch

On May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: SCOTUS backs generic firm Hikma in skinny label dispute
Next: Pfizer signs licence agreement with Chai for AI drug discovery

Related Stories

  • Regulatory

Replimune gets early August decision date for twice-rejected melanoma drug

pharminent June 26, 2026
  • Regulatory

Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use

pharminent June 25, 2026
  • Regulatory

MSD’s Keytruda-Padcev combo secures EC approval for MIBC

pharminent June 25, 2026

You May Have Missed

  • News

Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and Zepbound

pharminent June 26, 2026
  • News

Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms

pharminent June 26, 2026
  • Regulatory

Replimune gets early August decision date for twice-rejected melanoma drug

pharminent June 26, 2026
  • Pipeline

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms

pharminent June 26, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.